目的 考察单唾液酸四己糖神经节苷脂钠注射液联合血塞通注射液治疗脑梗死的临床疗效。方法 选择2016年1月-2017年1月上海市第四康复医院治疗的92例脑梗死患者作为研究对象，将患者随机分为对照组和治疗组，每组各46例。对照组患者静脉滴注血塞通注射液，600 mg加入到生理盐水250 mL中，1次/d。治疗组在对照组治疗的基础上给予静脉滴注单唾液酸四己糖神经节苷脂钠注射液，100 mg加入到生理盐水250 mL中，1次/d。两组患者均连续治疗14 d。观察两组患者的临床疗效，同时比较两组治疗前后的神经功能缺损评分、生活质量评分和炎症因子水平。结果 治疗后，治疗组的总有效率为76.1%，显著高于对照组的60.8%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的生理功能、生理职能、情感职能、社会功能、活力、躯体疼痛、精神健康、总体健康评分和总分均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组生活质量各项评分和总分均明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者NIHSS评分显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后治疗组NIHSS评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的血浆C反应蛋白（CRP）和纤维蛋白原（Fg）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组血浆CRP和Fg水平均明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 单唾液酸四己糖神经节苷脂钠注射液联合血塞通注射液治疗脑梗死具有较好的临床疗效，可显著改善患者的神经功能和生活质量，能降低炎症因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Monosialotetrahexosylganglioside Sodium Injection combined with Xuesaitong Injection in treatment of cerebral infarction.Methods Patients (92 cases) with cerebral infarction in the Shanghai Fourth Rehabilitation Hospital from January 2016 to January 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were iv administered with Xuesaitong Injection, 600 mg added into normal saline 250 mL, once daily. Patients in the treatment group were iv administered with Monosialotetrahexosylganglioside Sodium Injection on the basis of the control group, 100 mg added into normal saline 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the neurological deficit scores, quality of life scores, and the inflammatory factors levels in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the treatment group was 76.1%, which was significantly higher than 60.8% in the control group, and there were differences between two groups (P<0.05). After treatment, physiological function, physiological role, emotional role, social function, life vigor, body pain, mental health, general health scores, and total scores were significantly increased, and there were differences in the same group (P<0.05). After treatment, the scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the NIHSS scores in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the NIHSS scores in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the plasma CRP and Fg levels in two groups were significantly decreased, and there were differences in the same group (P<0.05). Ater treatment, the CRP and Fg levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).Conclusion Monosialotetrahexosylganglioside Sodium Injection combined with Xuesaitong Injection has significant clinical effect in treatment of cerebral infarction, can significantly improve the neurological function and quality of life, and reduce the level of inflammatory factors, which has a certain clinical application value.